About
AbTherx develops advanced transgenic mouse platforms for therapeutic antibody discovery, enabling the identification of human monoclonal and bispecific antibodies against challenging targets such as GPCRs and ion channels.
Explore AbTherx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.